Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 18;10:2040620719854171. doi: 10.1177/2040620719854171

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2019

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 2. — The activity of the monoclonal antibodies, daratumumab and elotuzumab, synergism with the immunomodulatory drugs and cyclophosphamide, and the role of checkpoint inhibition.

ADCC, antibody-dependent cellular cytotoxicity); CDC, complement-dependent cytotoxicity); ADCP, antibody-dependent cellular phagocytosis; FCgtammaR1, FC gamma receptor 1; IL, Interleukin; TNF, tumour necrosis factor; IFN, interferon; PD-L1, programmed death- ligand 1; PD-1, programmed death-1; MAPK/ERK, mitogen activated protein kinases/extracellular signal-regulated kinases.